相关实验视频

Updated: May 8, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

新辅助化疗对变异组织学局部晚期结肠癌的长期影响:倾向性得分匹配分析

Qiancheng Wang¹, Shiyang Jin¹, Zeshen Wang¹

¹Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin, China.

Cancer biology & therapy

|December 24, 2024

概括

新辅助化疗 (NAC) 有益于局部晚期结肠癌 (LACC) 的非性腺癌 (NMAC) 患者. 在粘膜腺癌 (MAC) 或结环细胞癌 (SRCC) 患者中,NAC并没有显著改善存活率.

科学领域:

在瘤学瘤学.
胃肠道手术胃肠道手术
化疗研究化疗研究

背景情况:

新辅助化疗 (NAC) 建议用于局部晚期结肠癌 (LACC),包括临床T4b病例.
由于临床试验数据不确定,LACC中NAC的长期存活益处仍在争论中.
确定从NAC中获益最多的患者子组对于个性化治疗策略至关重要.

研究的目的:

评估新辅助化疗 (NAC) 在局部晚期结肠癌 (LACC) 患者的疗效.
根据结肠癌的不同组织学亚型,评估NAC对生存结果的影响.

主要方法:

对3709名接受治疗切除 (2014-2018) 的LACC患者进行了回顾性分析.
新辅助化疗 (NAC) 和辅助化疗 (AC) 组之间的比较.
倾向性得分匹配 (PSM) 用于混调整;卡普兰-梅尔 (K-M) 曲线和日志等级测试用于生存分析.

主要成果:

与AC相比,接受NAC的非性腺癌 (NMAC) 患者的5年整体存活率 (OS) (76.3%对69.2%) 和无病存活率 (DFS) (67.2%对60.1%) 显著改善.
在粘膜腺癌 (MAC) 或结环细胞癌 (SRCC) 中,在NAC和AC组之间没有观察到OS或DFS的显著差异.

结论:

在LACC中NAC的预后值取决于组织学亚型.
非性腺癌 (NMAC) 可能预测在LACC患者中从NAC获得有利的长期生存益处.

关键词:

进行大肠切除术 (colectomy).结肠癌是什么意思结肠癌是什么意思新辅助性化疗是一种新辅助性化疗.幸存率幸存率生存率

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...